Using Remimazolam to Generate Hemodynamically Stable Burst Suppression: A Case Report and Literature Review

Remimazolam is a short-acting benzodiazepine that was approved by the United States Food and Drug Administration (FDA) in 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 min or less. Given its recent introduction, the use of remimazolam for ge...

Full description

Saved in:
Bibliographic Details
Main Authors: Chin Fung Kelvin Kan, Jacob E. Pollard
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Case Reports in Anesthesiology
Online Access:http://dx.doi.org/10.1155/cria/7512576
Tags: Add Tag
No Tags, Be the first to tag this record!